Clinical trials: Clopidogrel, completed
Acute Myocardial Infarction
To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.
Through the injection of Hearticellgram-AMI into acute myocardial infarction patients who are the primary targets of the drug, long term efficacy in the improvement of the left ventricle ejection fraction upon the first cell…
- Trial name
- NCT01652209
- Testing
- Hearticellgram-AMI
- Where
- 10 sites in South Korea
- Volunteers
- 90 people
- Sponsor
- Pharmicell Co., Ltd.
Acute Coronary Disease, Angina Unstable
Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS
The purpose of this study is to evaluate whether a higher dosage of clopidogrel with aspirin (two doses) will decrease the risk of ischemic complications (cardiac death (CV death), myocardial infarction (MI), stroke) after a…
- Trial name
- CURRENT/OASIS7 (NCT00335452)
- Testing
- Clopidogrel, acetylsalicyclic acid (ASA)
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 25,086 people
- Sponsor
- Sanofi
Stroke, Ischemic
Argatroban Combined With Antiplatelet Versus Antiplatelet for Acute Ischemic Stroke
Intravenous thrombolysis is considered as the first choice for ischemic stroke. In the recent years, endovascular therapy is demonstrated to be effective to treat ischemic with big vessel occlusion.
- Trial name
- NCT03552354
- Testing
- Argatroban plus dual antiplatelet
- Where
- China
- Volunteers
- 120 people
- Sponsor
- General Hospital of Shenyang Military Region
Heart Diseases, Coronary Disease
CES1 Carriers in the PAPI Study
This study builds, in part, upon preliminary results generated as part of the Pharmacogenomics Anti-Platelet Intervention (PAPI) Study (NCT00799396).
- Conditions
- Heart Diseases, Coronary Disease, Coronary Artery Disease, Cardiovascular Diseases
- Trial name
- NCT03188705
- Testing
- Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Acute Ischemic Stroke, Transient Ischemic Attack (TIA)
A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
The purpose of this clinical study is to determine whether the addition of an oral Factor XIa Inhibitor to Aspirin and Clopidogrel is more effective than standard therapy in secondary stroke prevention.
- Trial name
- AXIOMATIC-SSP (NCT03766581)
- Testing
- BMS-986177, Clopidogrel, Aspirin
- Where
- 424 sites in United States, Argentina and 27 more
- Volunteers
- 2,366 people
- Sponsor
- Bristol-Myers Squibb
Plaque, Atherosclerotic
Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation
Objectives: To compare the effects of clopidogrel versus ticagrelor on atherosclerotic plaque inflammation using serial FDG PET/CT imaging of carotid artery and ascending aorta.
- Trial name
- NCT01905566
- Testing
- Clopidogrel, Ticagrelor
- Where
- South Korea
- Volunteers
- 50 people
- Sponsor
- CHEOL WHAN LEE, M.D., Ph.D
Acute Coronary Syndrome
Pharmacokinetic/Pharmacodynamic Study of Vicagrel Capsules and Clopidogrel Tablets in Healthy CYP2C19 Normal Metabolizers
This clinical study will adopt an open-label, randomized, two-crossover design to explore the pharmacokinetic and pharmacodynamic profiles of Vicagrel Capsules and Clopidogrel Tablets in Healthy Subjects with CYP2C19 Normal…
- Trial name
- NCT07067775
- Testing
- Vicagrel Capsules, Clopidogrel Tablets
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM)
Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
Patients with diabetes mellitus (DM) and chronic kidney disease (CKD) are at increased risk of atherothrombotic events. Clopidogrel is the most widely used platelet P2Y12 receptor inhibitor in patients with coronary artery…
- Conditions
- Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), Coronary Artery Disease (CAD)
- Trial name
- NCT03774394
- Testing
- Clopidogrel, Clopidogrel active metabolite
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- University of Florida
Peripheral Arterial Disease
Effect of Plavix on NO (Nitrogen Monoxide) Production of the Endothelial Function
To determine whether in the laser Doppler flowmetric parameters characteristic of endothelial dysfunction at patients with clinically manifest atherosclerosis any change can be detected at plavix (clopidogrel) treatment.
- Trial name
- NCT00648453
- Testing
- Clopidogrel (Plavix)
- Where
- Hungary
- Volunteers
- 39 people
- Sponsor
- Sanofi
Acute Ischemic Stroke
Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME)
Stroke is a common cause of disability. The most common type of stroke, an ischemic stroke, is caused by a blood vessel in the brain getting blocked by a clot.
- Trial name
- CoPRIME (NCT07844603)
- Testing
- aspirin + clopidogrel, Aspirin
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University of Alberta
Inhibition on Platelet Aggregation
Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets
Study to see if platelet transfusion stop or lessen the effect of the drug on platelets
- Trial name
- NCT01744288
- Testing
- Ticagrelor, Clopidogrel, ASA
- Where
- United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cerebral Aneurysm
Ticagrelor vs Clopidogrel for Platelet Inhibition in Stenting for Cerebral Aneurysm
Part of interventional neuroradiology procedures for the treatment of selected cerebral aneurysms are now based on stenting. To reduce thromboembolic events, dual antiplatelet therapy (APT) combining aspirin and clopidogrel is…
- Trial name
- TIC-TAC (NCT02675205)
- Testing
- Clopidogrel, Ticagrelor, aspirin
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Platelet Dysfunction
clOpidogrel "resIstaNce" in a Selected Population of Patients at a Tertiary Cardiovascular Center in Trinidad
The aim of this study was to determine the prevalence of clopidogrel resistance among a selected group of patients undergoing elective percutaneous coronary intervention and to observe whether there was any south-Asian…
- Trial name
- POINT (NCT03667066)
- Testing
- Clopidogrel
- Where
- Trinidad and Tobago
- Volunteers
- 40 people
- Sponsor
- The University of The West Indies
Aorta-iliac Segment Lesion (C,D Type by TASC II)
Study of the AFB and Stenting of the Iliac Arteries
The aim of the study is to compare effectiveness and long-term results of aorta-femoral reconstructions and endovascular treatment in the patients with aorta-iliac lesions (TASC C,D).
- Trial name
- NCT02209350
- Testing
- Aorta-femoral bypass, Recanalization and stenting of aorta-iliac segment, Therapy: aspirin and clopidogrel
- Where
- Russia
- Volunteers
- 202 people
- Sponsor
- Meshalkin Research Institute of Pathology of Circulation
Acute Coronary Syndrome, Atrial Fibrillation
APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF
It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and…
- Conditions
- Acute Coronary Syndrome, Atrial Fibrillation, Coronary Artery Disease
- Trial name
- APPROACH (NCT02789917)
- Testing
- Dual Therapy, Triple Therapy
- Where
- 16 sites in Germany
- Volunteers
- 403 people
- Sponsor
- LMU Klinikum
Acute Myocardial Infarction
Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction
Early reperfusion strategies in tandem with remarkable advances in drugs and devices for treating myocardial infarction (MI) have contributed to a reduction in early mortality, but cardiovascular disease remains the leading cause…
- Trial name
- SEED-MSC (NCT01392105)
- Testing
- Mesenchymal stem cell, Control group
- Where
- 3 sites in South Korea
- Volunteers
- 80 people
- Sponsor
- Yonsei University
Atrial Fibrillation
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
There are insufficient data on the safety and efficacy of edoxaban plus antiplatelet therapy in subjects with atrial fibrillation (AF) following percutaneous intervention (PCI) with stenting.
- Trial name
- ENTRUST-AF-PCI (NCT02866175)
- Testing
- Edoxaban, Clopidogrel, Prasugrel
- Where
- 200 sites in Austria, Belgium and 16 more
- Volunteers
- 1,506 people
- Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
Platelet Dysfunction Due to Drugs
The Effects of loW Dose tIcagrelor on Platelet Function Testing in Patients With Stable Coronary arTery Disease
This study aims to assess the effects of low dose ticagrelor on platelet function testing in patients with stable coronary artery disease.
- Trial name
- TWIST (NCT04206176)
- Testing
- Ticagrelor
- Where
- Trinidad and Tobago
- Volunteers
- 25 people
- Sponsor
- The University of The West Indies
Coronary Artery Disease
Feasibility and Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Elective PCI
The purpose of this study is to determine if it is feasible and safe to use the REG1 Anticoagulation System instead of unfractionated heparin during percutaneous coronary intervention (PCI) in subjects with coronary artery…
- Trial name
- REVERSAL-PCI (NCT00715455)
- Testing
- REG1, Unfractionated Heparin
- Where
- 6 sites in United States, Argentina
- Volunteers
- 26 people
- Sponsor
- Regado Biosciences, Inc.
Myocardial Infarction, Diabetes Mellitus
Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus
Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor, more frequently clopidogrel, represents the standard of care for the long-term secondary prevention of atherothrombotic events in patients with…
- Conditions
- Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease
- Trial name
- OPTIMUS-5 (NCT02548650)
- Testing
- Vorapaxar, Clopidogrel, Aspirin
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- University of Florida